AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12766750
Drug: Intravenous calcium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous calcium chloride, n = 13
Trial: 1287557
Drug: Prenatal thyrotropin-releasing
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal thyrotropin-releasing hormone (TRH) treatment (400 micrograms i.v. every 8 h, one to four doses) plus 12 mg betamethasone (one or two doses)
Trial: 1287557
Drug: Prenatal thyrotropin-releasing
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal thyrotropin-releasing hormone (TRH) treatment
Trial: 17683491
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preparation)
Trial: 29533397
Drug: Same-day single
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day single dose of low-volume (SSL) polyethylene glycol (PEG)
Trial: 26564575
Drug: Neuromuscular exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular exercise (NEMEX) program, performed in groups twice weekly for 8 weeks, consisting of 11 exercises focusing on joint stability and neuromuscular control.
Trial: 16185242
Drug: Pre-packaging of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-packaging of antimalarial drug
Trial: 12363118
Drug: Standardized stepwise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized stepwise drug treatment regimen (SSTR)
Trial: 60209
Drug: Initial oral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial oral dose of 900 mg propafenon
Trial: 60209
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 300 mg propafenon at eight-hourly intervals
Trial: 60209
Drug: 1.0-1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0-1.5 mg propafenon per kg body weight by quick infusion
Trial: 30971234
Drug: Holistic physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holistic physical exercise training intervention once weekly for 15 weeks
Trial: 22946673
Drug: Pregabalin with
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin with associated treatments (antidepressants and mood stabilizers)
Trial: 19174803
Drug: Radiofrequency thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency thermal ablation (RF) and Percutaneous ethanol injection (PEI)
Trial: 59017
Drug: Human diploid
RxNorm normalized name: rabies vaccine, human diploid cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human diploid cell strain rabies vaccine (0.4 ml on day 0)
Trial: 59017
Drug: Human diploid
RxNorm normalized name: rabies vaccine, human diploid cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human diploid cell strain rabies vaccine (0‐1 ml on days 0, 3, 7, and 14)
Trial: 59017
Drug: Human diploid
RxNorm normalized name: rabies vaccine, human diploid cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human diploid cell strain rabies vaccine (0.1 ml into each limb on day 0)
Trial: 17178485
Drug: Methylprednisolone 1
RxNorm normalized name: methylprednisolone 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 1 mg/kg
Trial: 11791892
Drug: FP-spacer: fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP-spacer: fluticasone pressurised metered dose inhaler (Flixotide 250 microg ex-valve per actuation), eight puffs via a primed Volumatic 750-ml spacer.
Trial: 11791892
Drug: FP-neb: Flixotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP-neb: Flixotide Nebule 2 mg/2 ml via Pari LC Plus nebuliser.
Trial: 9230825
Drug: Latanoprost and
RxNorm normalized name: latanoprost and netarsudil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost and Physostigmine combination
Trial: 1773364
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of alfentanil
Trial: 25544263
Drug: sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugammadex 2 mg/kg
Trial: 29025888
Drug: Erdosteine 300
RxNorm normalized name: erdosteine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine 300 mg twice daily
Trial: 25410076
Drug: Salmon calcitonin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time a day for 15 days
Trial: 25410076
Drug: Salmon calcitonin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time every 3 days for 90 days
Trial: 25410076
Drug: Salmon calcitonin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time every 2 days for 30 days
Trial: 7597269
Drug: Bronchodilator therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator therapy
Trial: 16167973
Drug: 2.2 g
RxNorm normalized name: Vaporizer Safeguard 2.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 g co-amoxiclav (or 2 g cefotaxime if penicillin-allergic)
Trial: 12207636
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRI)
Trial: 10334546
Drug: Oral F‐AMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral F‐AMP 50 mg
Trial: 10334546
Drug: Oral F‐AMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral F‐AMP 70 mg
Trial: 2409845
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (group C)
Trial: 30595274
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment without any supervised exercise intervention
Trial: 22323895
Drug: Niacin extended-release/simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin extended-release/simvastatin (NER/S)
Trial: 19804455
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine for 4 days followed by gemtuzumab ozogamicin on day 5 (Arm A)
Trial: 19804455
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine for 4 days combined with liposomal daunorubicin for 3 days (Arm B)
Trial: 17561795
Drug: Once-daily glargine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily glargine (GL)
Trial: 17561795
Drug: Twice-daily 70/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily 70/30 aspart premix
Trial: 27112607
Drug: Reperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion therapy
Trial: 16082602
Drug: Not receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not receiving reperfusion therapy
Trial: 10456206
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance test in the morning (0830 h)
Trial: 10456206
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance test in the evening (2030 h)
Trial: 10456206
Drug: NEFA response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NEFA response to insulin in the morning
Trial: 10456206
Drug: NEFA response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NEFA response to insulin in the evening
Trial: 8642805
Drug: rilmenidine (1‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine (1‐2 mg/day)
Trial: 8960851
Drug: atenolol (50‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50‐100 mg/day)
Trial: 21047568
Drug: Fluvastatin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (3 times 40 mg at 0 hr, 24 hr, and 48 hr)
Trial: 21047568
Drug: Fluvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (40 mg at 0 hr) plus placebo (24 hr and 48 hr)
Trial: 15848261
Drug: Therapy combined
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy combined with standing balance training by biofeedback (BPM Monitor)
Trial: 12585949
Drug: Carvedilol (3.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (3.125 mg twice daily, uptitrated to 25 mg twice daily)
Trial: 10565463
Drug: CSF glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CSF glycine levels in newborns without HIE (12.49 micromol/l)
Trial: 16119597
Drug: morphine 1
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 1 mg
Trial: 28449402
Drug: lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lixisenatide 20 µg
Trial: 28449402
Drug: insulin-glulisine (iGlu)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insulin-glulisine (iGlu)
Trial: 23870608
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of ASA 100 mg and clopidogrel 75 mg
Trial: 23870608
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of ASA and clopidogrel
Trial: 23870608
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (fixed-dose and free combination)
Trial: 21898310
Drug: Preventive intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive intervention programme (watchful waiting, bibliotherapy, problem-solving treatment, re-referral to primary care)
Trial: 17898401
Drug: Gabapentin plus
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin plus dexamethasone (800 mg gabapentin and 8 mg dexamethasone IV)
Trial: 18840107
Drug: Gabapentin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (800 mg)
Trial: 11533837
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg per day of oral iron
Trial: 11533837
Drug: 16 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/kg per day of oral iron
Trial: 11533837
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both doses (8 mg/kg vs 16 mg/kg)
Trial: 9934543
Drug: Cefotaxime 50
RxNorm normalized name: cefotaxime 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 50 mg/kg twice-daily (n = 130)
Trial: 9934543
Drug: Cefotaxime 33.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 33.3 mg/kg three-times-daily (n = 128)
Trial: 8109809
Drug: Salbutamol delivered
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol delivered from a metered dose inhaler (MDI)
Trial: 25946929
Drug: 100,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100,000 IU of oral vitamin D per month for 6 months
Trial: 11535498
Drug: Myeloablative SCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloablative SCT (cyclophosphamide/high-dose total body irradiation)
Trial: 9573752
Drug: Gonadotropin‐Releasing Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin‐Releasing Hormone analogue (two injections monthly)
Trial: 2899773
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride 25 mg twice daily plus elemental calcium 1 g daily and a vitamin D2 supplement
Trial: 11986206
Drug: Standard cytarabine-based
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard cytarabine-based therapy
Trial: 9719109
Drug: External radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External radiation therapy plus temporary stereotactic iodine-125 implants delivering a minimum peripheral tumor dose of 60 Gy
Trial: 9719109
Drug: External radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External radiation therapy only delivering 50 Gray (Gy) in 25 fractions over 5 weeks
Trial: 8083913
Drug: Sequential gradient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential gradient pneumatic leg compression (SCD)
Trial: 17181922
Drug: Interferential currents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential currents (IFT) administered for 10 minutes daily for 5 days per week for two weeks
Trial: 17181922
Drug: Horizontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horizontal therapy (HT) administered for 40 minutes daily for 5 days per week for two weeks
Trial: 8738112
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (FO, 22 ml daily, containing 4.6 g of n‐3 fatty acids)
Trial: 8738112
Drug: Gemfibrozil (G,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (G, 900 mg daily)
Trial: 8738112
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (FO, 22 ml daily)
Trial: 1568520
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg O‐(beta‐hydroxyethyl)rutosides orally twice daily
Trial: 18520448
Drug: Pentavalent rotavirus
RxNorm normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent rotavirus vaccine (live, oral)
Trial: 10963018
Drug: Metaphonologically (MET)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaphonologically (MET) therapy
Trial: 10963018
Drug: Articulation‐based (ART)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articulation‐based (ART) therapy
Trial: 10963018
Drug: ART therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART therapy
Trial: 10963018
Drug: MET therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET therapy
Trial: 8855091
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 600 mg/day for 20 days
Trial: 6091476
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g preoperative dose, placebo at 8 and 16 hours later)
Trial: 31370809
Drug: 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg paricalcitol
Trial: 31370809
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg paricalcitol
Trial: 26325514
Drug: Dexmedetomidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2 to 0.7 μg/kg/h)
Trial: 26325514
Drug: Remifentanil (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.08 to 0.15 μg/kg/min)
Trial: 18056490
Drug: Standard pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pain management alone (typically intravenous narcotics)
Trial: 15749490
Drug: Sperm treatment
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sperm treatment with exogenous PAF (10(‐7) mol/L) in sperm-washing medium, direct swim-up technique, maximum of six IUI cycles
Trial: 15749490
Drug: Direct swim-up
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct swim-up technique without PAF treatment
Trial: 9094145
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day selegiline
Trial: 9094145
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day selegiline
Trial: 1553901
Drug: Indicine N-oxide
RxNorm normalized name: Pyridinethiol N-oxide
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indicine N-oxide at 2,000 mg/m2/day for 5 consecutive days
Trial: 1553901
Drug: Indicine N-oxide
RxNorm normalized name: Pyridinethiol N-oxide
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indicine N-oxide at 2,500 mg/m2/day for 5 consecutive days
Trial: 3964332
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B (soft gelatine capsule with liquid nifedipine)
Trial: 22996849
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid (6 mg non-particulate betamethasone)
Trial: 12209526
Drug: Celecoxib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100 mg, 200 mg)
Trial: 7747322
Drug: Diethylcarbamazine (DEC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC, 6 mg/kg)
Trial: 2153393
Drug: Chemotherapy (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cyclophosphamide 1 g m‐2 i.v. day 1, vincristine 2 mg i.v. day 1, etoposide 100 mg tds p.o. days 1‐3, repeated every 21 days)
Trial: 28098515
Drug: Ezetimibe (EZ)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZ) 10 mg/day
Trial: 28098515
Drug: Plant Sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant Sterol (PS) 2 g/day
Trial: 28098515
Drug: Ezetimibe +
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe + Plant Sterol (EZ+PS) 10 mg/day + 2 g/day
Trial: 28098515
Drug: Control (CT)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CT) group on same statin therapy
Trial: 19185647
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin for 1 year
Trial: 19185647
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus aspirin for 1 year
Trial: 9590187
Drug: ABLC (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABLC (5 mg/kg/d)
Trial: 9590187
Drug: AmB (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmB (0.6 to 1 mg/kg)
Trial: 3049485
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of naproxen sodium
Trial: 3049485
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of naproxen sodium
Trial: 19001024
Drug: Chlorthalidone/amlodipine/lisinopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone/amlodipine/lisinopril
Trial: 1629380
Drug: Trazodone, mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone, mean daily dose 235 +/- 10 mg, 10 weeks
Trial: 1629380
Drug: Clomipramine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine and fluoxetine
Trial: 6380301
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium diet (300 mg calcium/day)
Trial: 6380301
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium diet plus hydrochlorthiazide (25 mg twice a day)
Trial: 18388340
Drug: sarpogrelate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarpogrelate (100 mg TID)
Trial: 18388340
Drug: aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin (81 mg/d)
Trial: 8679834
Drug: Parenteral S-adenosylmethionine
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral S-adenosylmethionine (SAMe)
Trial: 1726758
Drug: Palliative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative treatment only
Trial: 1726758
Drug: Palliative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative and isoprinosine treatment
Trial: 1726758
Drug: Palliative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative and acyclovir treatment
Trial: 1726758
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (palliative, isoprinosine, and acyclovir)
Trial: 6219903
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet containing orphenadrine citrate and paracetamol ('Norgesic')
Trial: 28353116
Drug: 40-unit RCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-unit RCI twice a week
Trial: 28353116
Drug: 80-unit RCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-unit RCI twice a week
Trial: 18080763
Drug: IFN beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta‐1a plus RBV (1,000‐1,200 mg/day)